Cocrystal Joins Russell Microcap® Index
June 28 2021 - 8:00AM
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal”
or the “Company”), a clinical-stage biotechnology company
discovering and developing novel antiviral therapeutics that target
the replication machinery of influenza viruses, coronaviruses,
hepatitis C viruses and noroviruses, announces that it will be
added to the Russell Microcap® Index after the U.S. market opens
today, June 28, 2021.
“We are delighted that Cocrystal will now be
included in the Russell Microcap® Index, which is a broadly used
performance benchmark for smaller growth stocks in the U.S.,” said
James Martin, Cocrystal’s interim co-CEO and CFO. “This is a
notable milestone for Cocrystal that will further raise awareness
of our company within the global investment community as we advance
development of our antiviral programs including the planned
initiation of an influenza A Phase 1 trial in the third
quarter.”
Membership in the Russell Microcap® Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell a leading
global index provider determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $10.6
trillion in assets are benchmarked against Russell’s U.S. indexes.
For more information on the Russell Microcap Index and the Russell
indexes reconstitution, go to the “Russell Reconstitution” section
on the FTSE Russell website. The information on the FTSE Russell
website is not part of this press release.
About Cocrystal Pharma,
Inc.Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of coronaviruses
(including SARS-CoV-2), influenza viruses, hepatitis C viruses and
noroviruses. Cocrystal employs unique structure-based technologies
and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the advancement of our programs such as the planned
initiation of influenza A Phase 1 trial in the third quarter of
2021. The words "believe," "may," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "could," "target,"
"potential," "is likely," "will," "expect" and similar expressions,
as they relate to us, are intended to identify forward-looking
statements. We have based these forward-looking statements largely
on our current expectations and projections about future events.
Some or all of the events anticipated by these forward-looking
statements may not occur. Important factors that could cause actual
results to differ from those in the forward-looking statements
include, but are not limited to, the risks and uncertainties
arising from the impact of the COVID-19 pandemic on the national
and global economy and on our Company, including supply chain
disruptions and our continued ability to proceed with our programs,
including our influenza A program, our ability to complete the
preclinical and clinical trials, the ability of the contract
research organization to recruit subjects, the results of such
future preclinical and clinical studies, and general risks arising
from clinical trials and more generally, the development of
investigational drugs. Further information on our risk factors is
contained in our filings with the SEC, including our Annual Report
on Form 10-K for the year ended December 31, 2020. Any
forward-looking statement made by us herein speaks only as of the
date on which it is made. Factors or events that could cause our
actual results to differ may emerge from time to time, and it is
not possible for us to predict all of them. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by law.
Investor Contact:LHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024